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Abstract
Mantle Cell Lymphoma is a rare B-cell malignancy that can invade almost any structure in the body and recur
after short-lived clinical responses. The pathogenesis and clinical features are well defined, but management has
not yet been optimized. Induction with traditional immune-chemotherapy regimens that are used in other non-
Hodgkin lymphomas rarely generate durable remissions. Therefore, clinical research is needed to improve treatment
of de novo disease and to establish safe and effective regimens for maintenance and salvage options for relapsed
or refractory disease. This comprehensive review discusses disease pathogenesis and focuses on emerging
treatment paradigms using novel targeted therapies.
Keywords: Mantle cell lymphoma; Cyclin D1; MIPI score;
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Introduction
Mantle cell lymphoma (MCL) is an uncommon but aggressive
lymphoma, comprising about 6% of all non-Hodgkin lymphomas [1]
with a typical median survival of 5-7 years [2]. Patients are much more
commonly male and elderly [3] with a median age of onset of 68 years
[4]. The disease is less frequent in Asian countries [4]. Most cases are
advanced at presentation and often exhibit complete responses to
initial treatment followed by frequent relapses [3].
This neoplasm is characterized by mature B-lymphocytes that
infiltrate the lymph nodes, bone marrow, peripheral blood, and
extranodal sites [3]. Histologic appearance is homogenous with a
background of pink histiocytes that stain positively for cyclin D1,
surface immunoglobulin B-cell markers, and CD5 [3]. While the t
(11;14) (q13;q32) translocation is present in over 90% of MCL, other
translocations have been reported. Disease heterogeneity features both
a blastoid variant with a high Kiel 67 (Ki67) proliferation index, as well
as a more indolent variant that can be appropriately managed with a
watch and wait approach until symptomatic [3].
Younger, fit patients can be managed with intensive cytarabine-
containing chemotherapy alternating with hyperfractionated
cyclophosphamide, vincristine, doxorubicin, and dexamethasone
combined with rituximab (R-HyperCVAD) with or without
autologous stem cell transplantation for consolidation. Other patients
receive CHOP-like (cyclophosphamide, doxorubicin, vincristine,
prednisone) therapy plus rituximab. Substitution of vincristine with
the proteasome inhibitor bortezomib has emerged as a validated
treatment for both relapsed and untreated disease.
Awareness of prognostic factors through the validated MIPI score
[5], identification of potential transplant candidates, and careful
assessment of response to and tolerance of immunochemotherapies,
are all crucial determinants of both survival and quality of life.
Diagnosis
MCL can be distinguished by immunohistochemistry (IHC) with a
profile usually showing positivity for B-cell markers as well as CD5,
FMC7, CD43, and cyclin D1. Most cases are negative for CD10 and
CD23. The reciprocal translocation t (11;14) results in the
overexpression of cyclin D1 [6]. In less than 5% of cases, cyclin D1 and
t (11;14) may be negative in MCL if there is an otherwise typical IHC
profile, with over half of these cases revealing rearranged CCND2 and
consequent overexpression of cyclin D2 mRNA [7]. Most pathologic
findings and clinical features of cyclin D1-negative MCL appear
similar to those of cyclin D1-positive cases [8], and should be managed
the same.
Pathogenesis
The pathogenesis of mantle cell lymphoma (MCL) occurs through
two major events that cause a gain of function and loss of function.
Chromosome 11q13 holds the proto-oncogene CCND1, which
encodes cyclin D1, and its translocation to chromosome 14q32, the
locus of the immunoglobulin heavy chain complex (IGH), deregulates
the cell cycle at the G1/S phase transition and makes cyclin D1
constitutively overexpressed in otherwise normal B lymphocytes. Gain
of function occurs via t (11;14) translocation, causing BCL-1 over-
transcription. Loss of function occurs via 11q22-23 deletion, altering
the DNA damage pathway response. Thus, the cyclin D1 protein has a
major oncogenic effect through two different mechanisms [9].
MCL carries a high degree of genomic instability, with multiple
secondary chromosomal alterations. Its pathogenesis was traditionally
thought to derive from naïve B-cells in the pre-germinal center (e.g.
mantle zone) since the initial translocation event t (11;14) (q13;q32)
occurs during recombination of the V(D)J segments of the IGH
variable region (IGHV) in the bone marrow. However, the tumor is
composed of mature B lymphocytes. Antigen selection is now thought
to play an important role in pathogenesis for the 15-40% of MCLs that
carry IGHV hypermutations similar to those in chronic lymphocytic
leukemia [10].
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Cyclin D1 binds to CDK4 and CDK6, which phosphorylates
retinoblastoma 1 (RB1), thereby activating the transcription factor E2F
while promoting cyclin E/CDK2 activation to trigger entry into the S
phase of the cell cycle [11]. Additional oncogenic interactions by cyclin
D1 include chromatin remodeling and histone-modifying enzymes.
Secondary chromosome alterations that also affect DNA damage
response and cell survival pathways are now thought to facilitate
aggressive MCL because the CDKN2A locus (9p21), which encodes for
both the CDK inhibitor INK4a and the positive p53 regulator ARF, is
frequently deleted in these cases [11].
Classification
The round cell variant has a CLL-like clinical presentation that
tends to behave more like an indolent lymphoma. These cases usually
show a rather low cell proliferation (Ki-67 roughly 10%). On the other
hand, a blastoid variant occurring 5% of the time shows a much more
aggressive clinical course. Biological factors like high cell proliferation
(determined by Ki-67 staining) or p53 mutations and p16 deletions are
closely related to this MCL subtype. However, more than 80% of MCL
still presents with somewhat intermediate characteristics. Whereas
immediate initiation of treatment is indicated for the majority of
patients, select cases may be closely observed to more reliably estimate
the aggressiveness of the disease [12].
Prognostic markers
In 2008, Hoster et al. [5] devised a system to categorize MCL
patients’ relative survival probability by grading the following risk
factors: age, performance status, lactate dehydrogenase (LDH) level,
and white blood cell (WBC) count. This system is outlined in Table 1.
A MIPI combined biologic index (MIPIb) score of less than 5.7
classifies patients into a low-risk group comprising 44% of patients
with a median overall survival (OS) not reached; a score of 5.7 to less
than 6.2 yields an intermediate-risk group comprising 35% of patients
with median OS of 51 months; and a score of 6.2 or greater falls into
the high-risk group with 21% of the patients and median OS of 29
months. It is notable that the number of extranodal sites is not an
independent prognostic factor in the MIPI score. Tumor cell
proliferation, assessed on paraffin-embedded tissue by Ki-67, showed a
median value of 14.5% (range 1.2–91%). This value was also
prognostically significant using a cutoff point of 10%, and was
independent of the MIPI. Ki-67 of 30% has been proposed by the
NCCN as a cutoff for determining the aggressiveness of the disease,
but should not constitute an indication to begin treatment [13].
MIPIb Index
Score* Risk Patient percentage Overall survival
<5.7 Low risk 44% Not reached
5.7 to £ 6.2 Intermediate risk 35% 51 months
≥ 6.2 High risk 21% 29 months
Table 1: MIPI Score. *Survival probability by grading the following risk
factors: age, performance status, lactate dehydrogenase (LDH) level,
white blood cell (WBC) count, and Ki-67.
Induction Therapy
Stage I and non-bulky Stage II
Localized presentation, which is extremely rare, can be managed
with observation, radiation therapy, or a combination of radiation and
chemotherapy. Retrospective data suggests that use of radiotherapy
with or without chemotherapy engendered significantly better
progression-free survival (PFS) at 5 years (73% vs. 13%; p=0.001) with
a trend towards overall survival benefit, when compared to patients
who did not receive radiation [14]. Radiotherapy as a primary
treatment for stage 1-2 MCL patients analyzed retrospectively showed
curative results for 3.6% of patients, with 3-year OS of 93% [15].
Bulky Stage II, Stage III, and Stage IV
Enrollment in clinical trials is recommended for eligible patients
with systemic disease, in whom no cure is currently available. In highly
select cases in which the patient is asymptomatic, advanced disease can
also be managed with a watch and wait approach.
R-HyperCVAD (rituximab, cyclophosphamide, vincristine,
doxorubicin, and dexamethasone alternating with high-dose
methotrexate and cytarabine) is considered a preferred aggressive
regimen in patients who can tolerate considerable toxicity. A phase II
study of 97 treatment-naïve patients with advanced MCL showed
failure-free survival of 64% and overall survival of 82% at 3 years, and
median overall survival not yet reached at 10 years follow-up [16]. The
SWOG 0213 phase II multicenter trial of newly diagnosed patients
under the age of 70 who received R-HyperCVAD yielded PFS of 4.8
years and OS of 6.8 years, with 2-year PFS of 63% and OS of 76% [17].
The Nordic regimen includes induction immunochemotherapy
with rituximab plus maxi-CHOP (cyclophosphamide, vincristine,
doxorubicin, prednisone) alternating with rituximab and high-dose
cytarabine. The Cancer and Leukemia Group B (CALGB) regimen
features induction with rituximab-methotrexate with augmented
CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) for
at least 2 cycles, with an additional cycle if the bone marrow contains
greater than 15% involvement by MCL.
A phase III randomized trial of the German Low Grade Lymphoma
study group [18] evaluated the addition of rituximab to CHOP
chemotherapy (cyclophosphamide, doxorubicin, vincristine,
prednisone) in treatment-naïve patients with advanced MCL aged 65
and younger. R-CHOP showed significantly better overall response
rate (94% vs. 75%), complete remission rate (34% vs. 7%) and median
time to treatment failure (21 months vs. 14 months) than CHOP.
However, PFS and OS outcomes were not superior. R-CHOP can also
be alternated with R-DHAP (rituximab, dexamethasone, cisplatin,
cytarabine) or R-ICE (rituximab, ifosfamide, carboplatin, etoposide) in
sequence.
For elderly patients or those with poor performance status,
bendamustine plus rituximab (BR) has shown superior PFS than R-
CHOP (35 months vs. 22 months; HR=0.49, 95% CI 0.28-0.79;
p=0.0044) in primary MCL according to subgroup analysis of the
phase III STiL study [19]. Of note, adverse events and grade 3 and 4
toxicities were significantly less in the BR treatment arm.
Another less aggressive induction regimen to gain FDA approval is
VR-CAP (bortezomib, rituximab, cyclophosphamide, doxorubicin,
prednisone). When compared to R-CHOP in patients who were not
transplant-eligible, front-line VR-CAP showed superior PFS (24.7 vs.
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14.4 months, p<0.001) and CR rate (48% vs. 41%) with a trend towards
OS benefit (64% vs. 54%) in a phase III randomized study [20].
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Table 2: Induction therapy.
Of note, VR-CAP incurred slightly more high-grade adverse events
(93% vs. 84%), but most were considered manageable. VR-CAP was
again compared to R-CHOP in a recently published study of 487
patients with at least stage II disease [21]. The median PFS was 14.4
months in the R-CHOP group and 24.7 months in the VR-CAP group
(hazard ratio favoring the VR-CAP group, 0.63; p<0.001), and there
was consistent progression-free survival benefit across all prespecified
subgroups and irrespective of MIPIb and Ki-67 score [21]. VR-CAP is
currently the only first-line regimen approved by the FDA.
A Summary of the treatment regimens is presented in Table 2.
Consolidation therapy
Following successful induction with R-HyperCVAD or CHOP-like
immunochemotherapy, high-dose therapy (HDT) with one cycle of
etoposide, cytarabine, and rituximab and one cycle of carmustine,
etoposide, and cyclophosphamide has been effectively followed by
autologous stem cell rescue (ASCR). Thirty-three patients treated at
MD Anderson after achieving first remission with HyperCVAD with
or without rituximab achieved 5-year disease-free survival of 42% and
OS of 77% [22], with 100% OS rate in those patients with a low serum
beta-2 microglobulin level. Long-term follow-up showed a median
PFS of 42 months and OS of 93 months [23]. Non-randomized
analysis suggests an improved PFS in transplanted patients who were
induced with HyperCVAD (with or without rituximab) rather than
CHOP (with or without rituximab) [24].
Post-induction maintenance therapy with rituximab has been
shown to provide extended disease control for patients who cannot
undergo high-dose therapy and stem cell transplantation. In one pilot
phase II study of 22 patients with newly diagnosed MCL, a dose-
reduced R-HyperCVAD (omitting methotrexate and cytarabine)
followed by maintenance therapy with rituximab for 5 years yielded a
PFS of 37 months and median OS not reached, with acceptable toxicity
[25]. Additional studies have also shown promising data for rituximab
maintenance after R-CHOP induction [26,27], and it remains unclear
whether first-line consolidation with high-dose chemotherapy with
autologous stem cell rescue (HDT/ASCR) provides an advantage over
rituximab maintenance in patients of any age. No randomized trial
data are currently available to compare intensive consolidation
regimens against maintenance therapy.
Table 3 provides a summary of the current consolidation/
maintenance regimens.
Treatment Study Overall survival rate (OS) Progression Free
Survival (PFS)
HyperCVAD +/- Rituximab Long-term follow-up of auto-SCT in pts with diffuse
MCL in first CR (21)
77%-100% (patients with low
serum B2 Microglubulin)
42 months
Long-term follow-up HyperCVAD +/- Rituximab followed
by MD Anderson after achieving first remission
Mature results of the M.D. Anderson Cancer Center
risk-adapted transplantation strategy in MCL (22)
93 months 42 months
Table 3: First-line consolidation.
Second-line therapy
Second-line consolidation therapy can be pursued with autologous
or allogeneic stem cell transplantation (SCT) following non-
myeloablative or myeloablative conditioning regimens. A study of 112
patients who had previously failed conventional chemotherapy
underwent a preparative conditioning regimen that consisted of
etoposide, cyclophosphamide, mesna, and fractionated total-body
irradiation (TBI). Patients who were not eligible for TBI because of
prior exposure to radiation received BEAM (carmustine–etoposide–
cytarabine–melphalan) for conditioning instead. Graft-versus-host
disease (GVHD) prophylaxis consisted of a combination of
cyclosporin or tacrolimus with mini-dose methotrexate and/or
methylprednisolone. Nine patients received interferon-α maintenance
after autologous SCT. Allo-SCT in 44 patients resulted in lower
recurrence rates but higher treatment-related mortality rates than the
68 patients who underwent high-dose therapy with autologous stem
cell transplantation [28]. Outcomes were initially more favorable for
the autologous SCT group (significant only for day 100 mortality);
however, this pattern changed over time. A plateau was seen amongst
the allogeneic SCT group at 44 months after transplantation for OS
and at 24 months for DFS, whereas there was a continuous pattern of
treatment failure in the autologous SCT group. The improved OS
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among the allogeneic SCT group was not statistically significant
(p>0.05) but the improved DFS was significant (p=0.01). A similar
pattern of DFS was observed when 19 patients with chemoresistant
disease who underwent allogeneic SCT were compared with 26
patients with chemosensitive disease who underwent autologous SCT
(p=0.04). The rate of disease progression was significantly higher in
the autologous SCT group (74%; 95% CI 59% to 88%) than in the
allogeneic SCT group (19%; 95% CI 9% to 38%) with p=0.003 [28].
Additional regimens suitable for use in first relapse include:
bendamustine with or without rituximab [29]; cladribine [30]; FC
(fludarabine plus cyclophosphamide) with or without rituximab;
FCMR (fludarabine, cyclosphamide, mitoxantrone, and rituximab);
FMR (fludarabine, mitoxantrone, and rituximab); PCR (pentostatin,
cyclophosphamide, and rituximab); and PEPC (prednisone, etoposide,
procarbazine, cyclophosphamide with or without rituximab).
Novel Agents
Bortezomib is approved by the U.S. Food and Drug Administration
(FDA) for relapsed or refractory MCL based on the phase II
PINNACLE trial, in which bortezomib induced an overall response
rate of 33% (CR in 8%), with a median duration of response of 9
months and median time to progression of 6 months [31]. Long-term
follow-up confirmed these effects [32]. Bortezomib combined with
rituximab has shown activity in heavily pre-treated patients with
relapsed/refractory disease.
The immunomodulating agent, lenalidomide, has shown efficacy in
relapsed or refractory aggressive non-Hodgkin lymphoma, with subset
analysis of MCL patients showing an ORR of 35% and CR rate of 12%
at a median follow-up of 12 months in a phase II trial [33]. In this
study the duration of response was 16 months, and the median PFS
was approximately 9 months.
Another recent phase II study of patients with rituximab-resistant
B-cell lymphomas [34] treated 43 patients with lenalidomide 10 mg by
mouth daily for 8 weeks followed by 4 weekly doses of rituximab 375
mg/m2 intravenously. Six out of the eleven patients with MCL showed
a clinical response (3 CR, 1 Cru, 2 PR); the addition of rituximab did
not change the ORR, although two PR improved to CR [4].
The small-molecule Bruton’s tyrosine kinase (BTK) inhibitor,
ibrutinib, has shown promising activity in several B-cell malignancies.
Subgroup analysis of phase I data in 9 patients with relapsed and/or
refractory MCL showed response in 7 patients, including a CR in 3
patients, with no dose-limiting toxicities and no significant
myelosuppression even with the full dose of 560 mg daily [35]. A
multicenter phase II trial of 111 patients who had been previously
treated with bortezomib and/or rituximab-containing regimens, 72%
of whom had advanced disease and 42% of whom had high-risk MIPI
scores, showed an ORR of 68% with CR rate of 21% after 15 months of
ibrutinib [36]. The median duration of response was 17.5 months,
median PFS was 14 months, and estimated OS rate at 18 months was
58%. The response rates appeared to increase with longer duration of
therapy. In November 2013, the FDA approved ibrutinib to treat MCL
on the basis of an “unprecedented” response. The most common
adverse event rated grade ≥3 were neutropenia (16%),
thrombocytopenia (11%), anemia (10%), pneumonia (6%), diarrhea
(6%), fatigue (5%) and dyspnea (5%). The use of ibrutinib causes a
transient lymphocytosis that resolves after an average of 8 weeks, and
caused grade ≥3 bleeding events in 5% of patients [37]. Thus, ibrutinib
is emerging as a potential preferred salvage option due to ease of daily
oral dosing and favorable side effect profile.
Although ibrutinib can extend the lives of heavily treated, relapsed,
or refractory patients with mantle cell lymphoma (MCL), many
become resistant to the drug. Analysis of longitudinal functional
genomics in MCL [38] showed that 30% of the patients who developed
resistance to ibrutinib expressed high levels of activated
phosphatidylinositol-3 kinase (PI3K-AKT) and cyclin-dependent
kinase 4 (CDK4). (PI3K-AKT proteins promote survival; CDK4 drives
MCL cells through the cell cycle.) These two mechanisms appeared to
override ibrutinib’s inhibitory action in resistant cells. An
experimental selective CDK4/CDK6 inhibitor, palbociclib, has
demonstrated cytotoxicity against the mutated BTKC481S protein.
Stepwise treatment with palbociclib followed by ibrutinib, or
palbociclib followed by the PI3K pathway inhibitor, idelalisib, which is
FDA-approved to treat CLL, might treat MCL patients who initially do
not respond to ibrutinib. Or, the drugs given together might prevent
resistance.
A 48-week study using idelalasib [39] evaluated 39 patients with
relapsed or refractory mantle cell lymphoma patients who had
received a median of four prior therapies. Overall, nine (18%) patients
discontinued therapy due to adverse effects including diarrhea,
transaminase elevations, pneumonia, and acute renal failure. Thirty-
three (84.6%) patients had some reduction in lymph node size, with
CR in two (5%) patients, PR in 14 (35%) patients, and stable disease in
nineteen (47.5%) patients.
Table 4 provides a summary of the novel agents used in MCL.
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Table 4: Novel agents.
Conclusion
Mantle cell lymphoma is an incurable but increasingly well
characterized clinicopathologic entity that unfortunately poses
persistent obstacles in achieving durable responses with available
treatment regimens. Early stage disease is rare, but limited available
data suggests that radiation with or without chemotherapy can
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effectively manage limited, non-bulky distribution. For advanced
disease, referral for enrollment in prospective clinical trials should be
pursued. Based on individual patients’ performance features, they can
be managed up-front with either observation, R-HyperCVAD, CHOP-
like chemotherapy, or less aggressive induction regimens including
bendamustine and rituximab. Relapsed and refractory disease carries a
poorer prognosis, but novel agents including bortezomib,
lenalidomide, and ibrutinib have shown promising efficacy and
tolerability. Further randomized data are needed to establish clear
standards of care and improve rates of survival and quality of life.
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